LORELEI: taselisib boosts breast tumor shrinkage #ESMO17

da Salute H24 — 9 settembre 2017 alle 11:41


Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid. 

“We were able to detect a reduction in tumor size after only 16 weeks of treatment, compared… Continua »

AntonioCaperna

Scrivi un commento